Relationship of Antibiotic Treatment to Recovery after Acute FEV1 Decline in Children with Cystic Fibrosis
Results: Logistic regression of 9,875 patients showed that new antibiotic treatment was associated with an increased likelihood of recovery to 90% of baseline (P < 0.001), especially for hospitalization compared with no new antibiotic (odds ratio [OR], 2.79; 95% confidence interval, 2.41-3.23). K...
Gespeichert in:
Veröffentlicht in: | Annals of the American Thoracic Society 2017-06, Vol.14 (6), p.937-942 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Results: Logistic regression of 9,875 patients showed that new antibiotic treatment was associated with an increased likelihood of recovery to 90% of baseline (P < 0.001), especially for hospitalization compared with no new antibiotic (odds ratio [OR], 2.79; 95% confidence interval, 2.41-3.23). Keywords: epidemiology; respiratory function tests; spirometry; adolescent Patients with cystic fibrosis (CF) experience acute declines in lung function often associated with symptoms of increased cough and sputum production (1, 2). Methods The Epidemiologic Study of Cystic Fibrosis (ESCF) is a prospective, encounter-based, multicenter observational study of patients with CF in North America from 1994 to 2005 including over 30,000 participants (14). Probability of treatment following acute decline in lung function in children with cystic fibrosis is related to baseline pulmonary function. 9 Morgan WJ, VanDevanter DR, Pasta DJ, Foreman AJ, Wagener JS, Konstan MW; Scientific Advisory Group; Investigators and Coordinators of Epidemiologic Study of Cystic Fibrosis. Forced expiratory volume in 1 second variability helps identify patients with cystic fibrosis at risk of greater loss of lung function. Effectiveness of home treatment for patients with cystic fibrosis: the intravenous administration of antibiotics to treat respiratory infections. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. |
---|---|
ISSN: | 2329-6933 2325-6621 |
DOI: | 10.1513/AnnalsATS.201608-615OC |